GLP1R and metabolic dysfunction-associated steatotic liver disease: Recent studies have shown that GLP-1R agonists can significantly improve hepatic fat content and liver function indexes in patients with MASLD, thereby reducing the risk of progression to Chronic Liver Disease in patients with MASLD (Singh et al., 2024; Soresi and Giannitrapani, 2024).